Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31507530 | 1.00 | DYRK1A (0.46) | DYRK1ACDK9CYP2A6CHRNA7 | |
| SCHEMBL8312831 | 0.73 | DYRK1A (0.46) | DYRK1ACDK9CYP2A6 | |
| SCHEMBL5332147 | 0.73 | DYRK1A (0.46) | DYRK1ACDK9CYP2A6CHRNA7 | |
| SCHEMBL6647229 | 0.73 | DYRK1A (0.59) | DYRK1ACDK9 | |
| SCHEMBL5308681 | 0.73 | DYRK1A (0.46) | DYRK1ACDK9CYP2A6CHRNA7 | |
| SCHEMBL8562451 | 0.72 | DYRK1A (0.46) | DYRK1ACDK9 | |
| SCHEMBL7709496 | 0.72 | DYRK1A (0.42) | DYRK1ACDK9 | |
| SCHEMBL16840467 | 0.70 | NCF1 (0.45) | DYRK1A | |
| SCHEMBL18937628 | 0.69 | DYRK1A (0.42) | DYRK1ACDK9 | |
| SCHEMBL6432195 | 0.68 | CYP2A6 (0.44) | DYRK1ACDK9CYP2A6CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| EP-4522608-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023217906-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| WO-2016100349-A2 | BICYCLIC AZAHETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100349-A2 | BICYCLIC AZAHETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | DYRK1A 2524/4885CDK9 408/4885CYP2A6 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.